Small Intestinal Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma that arises from the small intestine. Histologic variants include mucinous adenocarcinoma and signet ring cell carcinoma. 
Small intestinal adenocarcinomas most frequently harbor alterations in TP53, KRAS, APC, PIK3CA, and ERBB2 .
TP53 Mutation, KRAS Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and KRAS Exon 2 Mutation are the most common alterations in small intestinal adenocarcinoma .
There are 5 clinical trials for small intestinal adenocarcinoma, of which 4 are open and 1 is completed or closed. Of the trials that contain small intestinal adenocarcinoma as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open).
BRAF and ERBB2 are the most frequent gene inclusion criteria for small intestinal adenocarcinoma clinical trials .
Slc6a8 inhibitor rgx-202, xl888, and avelumab are the most common interventions in small intestinal adenocarcinoma clinical trials.
Significant Genes in Small Intestinal Adenocarcinoma
BRAF is altered in 8.82% of small intestinal adenocarcinoma patients .
BRAF is an inclusion eligibility criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
ERBB2 is altered in 13.24% of small intestinal adenocarcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.